What are the possible side effects of Carpisetin/Tunicote?

Capivasertib is a new oral AKT inhibitor developed by AstraZeneca for the treatment of patients with hormone receptor-positive, HER2-negative advanced breast cancer who carry PIK3CA, AKT1 or PTEN gene mutations. The drug interferes with the growth and metabolism of tumor cells by inhibiting the AKT signaling pathway, thereby delaying disease progression. Although it has shown remarkable efficacy and innovation in clinical application, like all targeted drugs, capicipositi may also cause a series of adverse reactions related to its mechanism of action.

Based on the post-marketing safety data, the most common adverse reactions of carpiseti include gastrointestinal reactions, skin reactions and metabolic abnormalities. Some patients may experience mild to moderate diarrhea, nausea or loss of appetite in the early stages of medication, which is related to the temporary impact of the medication on cells in the digestive system. If the symptoms are mild, they can usually be relieved by supplementing fluids, electrolytes or short-term symptomatic treatment. In addition, because the AKT pathway is closely related to insulin signaling, some patients may develop hyperglycemia or abnormal glucose tolerance, so doctors usually monitor blood sugar changes during medication.

Skin adverse reactions are also common, such as rash, itching, or mild scaling. Such symptoms often occur in the early stages of treatment and can generally be controlled by adjusting the dose or using anti-allergic drugs for a short period of time. Some patients also report fatigue, stomatitis, or mild increases in liver function parameters, but these are usually reversible. Compared with traditional chemotherapy drugs, carpisetin has a milder toxicity spectrum, and most side effects can be effectively managed under the guidance of a doctor.

It needs to be emphasized that the occurrence rate of adverse drug reactions is related to individual genetic background, medication time and combination treatment plan. Clinically, doctors will adjust the dosage according to patient tolerance to ensure efficacy while reducing the risk of side effects. Overall, the safety of carpisetin is considered acceptable, and its side effect characteristics are consistent with the AKT pathway inhibition mechanism, providing new ideas for precise medication in the era of targeted therapy.

Reference materials:https://www.drugs.com/mtm/capivasertib.html